Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus tiotropium + salmeterol/fluticasone in moderate to severe COPD
2015-000114-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 with Tiotropium + salmeterol/fluticasone (2 arms). Primary endpoint: Mean change from baseline in post-dose trough FEV1. Started Aug 2015; status: completed.
02
Drugs
indacaterol + glycopyrroniumtiotropiumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-000114-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000114-22.